Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral v…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.42 | $-0.66 | $-0.60 |
| Estimado | — | $-0.21 | $-0.24 | $-0.26 |
| Sorpresa | — | -100.0% | -175.0% | -130.8% |
| Métrica | VALN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 38.7% | 57.4% | -18.7% |
| Operating Margin | -47.0% | -34.4% | -12.6% |
| Net Margin | -66.0% | -32.5% | -33.5% |
| FCF Margin | -32.8% | -12.6% | -20.2% |
| ROE | -108.5% | -39.2% | -69.3% |
| ROA | -28.9% | -30.9% | +2.1% |
| Current Ratio | 2.38 | 2.73 | -0.35 |
| Debt / Equity | 1.52 | 0.28 | +1.24 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -28.9% | — |
| ✗Flujo de caja operativo positivo | −€53M | −€67M |
| ✗Rentabilidad sobre activos al alza | -28.9% | -2.4% |
| ✓Caja operativa/activos supera al ROA | -13.3% | ROA -28.9% |
| ✗Menos deuda a largo plazo | 40.4% | 33.3% |
| ✗Mejor liquidez (ratio corriente) | 2.38 | 2.61 |
| ✗Sin aumentar el nº de acciones | 168M | 146M |
| ✗Margen bruto al alza | 38.7% | 41.9% |
| ✓Rotación de activos al alza | 0.44 | 0.34 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -32.8% |
| ✗ROCE > 10 % | -26.9% |
| ✗Ventas > 5 %/año (3 años) | -21.5% |
| ✓Deuda neta/EBITDA < 3x | -1.1x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 51.4% |
Valneva SE cotiza a 5.61 USD y tiene una capitalización bursátil de $532M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud